Azacitidine is used to treat myelodysplastic syndromes.
Azacitidine is a cytosine nucleoside analog that exerts anti-tumor effects in the human body by demethylating DNA and directly killing abnormal hematopoietic cells in the bone marrow. And myelodysplastic syndrome is a malignant disease of bone marrow hematopoietic system, with pathological hematopoiesis and primitive cell increase in bone marrow, and demethylation therapy is an important therapeutic means for treating myelodysplastic syndrome.
Therefore, Azacitidine is available for the treatment of myelodysplastic syndromes. Myelodysplastic syndromes have a high risk of transformation to acute leukemia, and when myelodysplastic syndromes transform to acute leukemia, combination chemotherapy with Azacitidine-containing regimens may also be used.
Patients with myelodysplastic syndromes need to be seen by a hematologist in a timely manner to have their condition and prognosis evaluated by bone marrow aspiration and biopsy, FISH, and other tests, and then have a specialist develop an individualized treatment plan based on the patient’s specific condition.